FOR IMMEDIATE RELEASE

AVIVAGEN ANNOUNCES VOTING RESULTS FOR THE ELECTION OF ITS DIRECTORS

Ottawa, ON / TNW-Accesswire / April 8 2016/ – Avivagen Inc. (TSXV: VIV, OTC Pink: CHEXF), a life sciences company commercializing products to replace the antibiotics used in livestock feeds, announces the results of shareholder voting for the election of its directors

Avivagen is pleased to announce that each of the nominees proposed as directors in the management information circular dated February 23, 2016 was duly elected as a director of Avivagen by a majority of the votes cast by shareholders present in person or by proxy at the Annual Meeting of Shareholders held in Ottawa, Ontario on April 5, 2016.

The voting results are detailed below:

Nominee	% of Votes Cast at the Meeting which were Cast For the Election of Directors	% of Votes Cast at the Meeting which were Withheld From Voting
Kym Anthony	97.69%	2.31%
David Allan	98.25%	1.75%
Graham Burton	98.21%	1.79%
Vanessa Grant	97.65%	2.35%
Cameron Groome	98.21%	1.79%
David Hankinson	98.21%	1.79%
Paul Mesburis	98.03%	1.97%

Mr. Amin Khalifa did not stand for re-election as a Director and Kym Anthony commented that "the Board and management would like to extend their appreciation for the services Amin Khalifa has rendered to Avivagen since 2010". Mr. Anthony also extended his appreciation for Paul Mesburis running for election and joining Avivagen's Board of Directors and assuming the role of Audit Chair.

Mr. Paul Mesburis is a Chartered Professional Accountant and Chartered Financial Analyst, with more than twenty years of international experience in financial and capital markets. Mr. Mesburis capital markets experience encompasses senior roles for both buy-side and sell-side firms. On the buy-side, Mr. Mesburis has managed portfolios for investment strategies in both debt and equities. On the sell-side, Mr. Mesburis investment experience includes senior roles in mergers and acquisitions, investment banking, and institutional equity research at both global and domestic bank-owned investment dealers. Mr. Mesburis views on investments have been quoted in the media, including Report on Business of The Globe and Mail and the Financial Post, as well as being the subject of features on BNN – Business News Network. In 2012, he was honoured with a Canadian Lipper Fund Award which recognizes funds that have excelled in delivering consistently strong risk-adjusted performance, relative to their peers. Mr. Mesburis is a Director and Chair of the Audit & Risk Committee of ProMetic Life Sciences Inc., and a Director of EEStor Corp. He received his Master of Business Administration degree from the Schulich School of Business at York University and his Bachelor of Arts degree from the University of Toronto.

A meeting of the duly appointed Board of Directors followed the annual general meeting at which the directors reviewed the progress of the corporation and discussed business matters.

About Avivagen Inc.

Avivagen Inc. is a publicly-listed life sciences company trading on the TSX Venture Exchange under the ticker symbol “VIV” and on OTC Pink as “CHEXF.” The Company is developing scientifically-proven products for replacing antibiotics in livestock feeds and to benefit human and animal health. Its target markets include enhancing productivity and health in livestock, companion animal quality-of-life, and maintaining optimal health in humans.

Avivagen is based in partnership facilities of the National Research Council of Canada (NRC) - in Ottawa, Ontario and Charlottetown, Prince Edward Island. For more information, visit **www.avivagen.com**.

About Avivagen’s Technology

Avivagen’s proprietary and patented technology derives from its discovery that carotenoid oxidation produces oxygen copolymer products that have beneficial immunological properties. Avivagen’s commercial-stage application of its inventions is fully oxidized beta-carotene (“OxBC”), OxC-beta™ Technology (“OxC-beta”). Avivagen has discovered that OxC-beta can help an animal’s own systems to maintain and enhance health by supporting immune function and calming excess inflammation. Avivagen is developing OxC-beta to replace the antibiotics used for disease prevention and growth promotion in livestock feeds, to enhance quality of life of companion animals and to help maintain optimal health in humans. Avivagen’s commercial products are OxC-beta™ Livestock (Kingdom of Thailand), Vivamune™ Vital Health^3 Chews (U.S.) and Oximunol™ Chewable Tablets (U.S.).

Forward Looking Statements

This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions. Statements about uses of the technologies described in this news release, including their importance to animal or human health, their novelty, safety, efficacy or affordability, or management’s opinions, are all forward looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Such Avivagen risks and uncertainties include, but are not limited to, the following: its ability to continue as a going concern. Accordingly, readers should not place undue reliance on forward-looking statements. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information:

Avivagen Inc.
Cameron Groome, CEO & President
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Head Office Phone: 613-949-8164 Website: www.avivagen.com

Renmark Financial Communications Inc.
Bettina Filippone: bfilippone@renmarkfinancial.com
Laura Welsh: lwelsh@renmarkfinancial.com
Telephone: 416-644-2020 or 514-939-3989
Website: www.renmarkfinancial.com